Periodic fever syndromes, autoinflammatory diseases, Still’s disease and MAS/HLH
Ali Abdul-Sater, PhD
York University
Toronto, ON, Canada
Disclosure(s): No financial relationships with ineligible companies to disclose
Michael Pillinger, MD
New York University Grossman School of Medicine
New York,, NY, United States
Disclosure(s): Federation Bio: Consultant (Ongoing); Fortress Bioscience: Consultant (Ongoing); Hikma Pharmaceuticals: Grant/Research Support (Ongoing); Horizon Therapeutics: Consultant (Ongoing), Grant/Research Support (Ongoing); Sobi: Consultant (Ongoing)
The management of gouty arthritis is focused on treating pain and inflammation due to acute flares and preventing urate crystal deposition. A challenge associated with the successful management of gouty arthritis is increased safety concerns associated with colchicine and NSAIDs to manage acute pain. While there has been recent progress that shows interleukin-1 inhibitors may be useful alternatives for flare prevention, further studies are needed to identify novel targets in the management of acute pain and inflammation in the management of gout. This session will focus on recent studies that have identified new targets in pre-clinical models of gout that may have the potential to develop investigational new therapies for gouty arthritis.
Speaker: Ali Abdul-Sater, PhD – York University
Speaker: Michael Pillinger, MD – New York University Grossman School of Medicine